Skip to main content
. 2024 Mar 2;16(5):1032. doi: 10.3390/cancers16051032

Figure 3.

Figure 3

FDA-approved anticancer peptides (1989–2023). ADC, antibody drug conjugate; GnRH, gonadotropin-releasing hormone; PRRT, peptide receptor radionuclide therapy; PSMA, prostate-specific membrane antigen.